$AMRN Promotes Joseph T. Kennedy to Executive Vice President


Amarin Promotes Joseph T. Kennedy to Executive Vice President, General Counsel and Strategic Initiatives

Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the promotion of Joseph T. Kennedy to Executive Vice President, General Counsel and Strategic Initiatives.

With more than 20 years of industry experience, Mr. Kennedy has contributed significantly to progress at Amarin since joining the company in December 2011 as Senior Vice President, General Counsel. Kennedy’s recent accomplishments include his role in leading Amarin to two significant federal court rulings: The First Amendment-based federal court declaration allowing Amarin’s promotion of truthful and non-misleading off-label information about Vascepa®(icosapent ethyl) capsules and the first successful judicial challenge to a denial of five-year, NCE exclusivity since the Hatch-Waxman Act was passed in 1984. Kennedy is also credited with leading Amarin’s strategy in the successful prosecution of over 40 patents designed to protect the Vascepa franchise into 2030 and in the recent dismissal of a securities class action suit against Amarin. He also played an important role supporting Amarin business development in the establishment of Amarin’s U.S. Vascepa co-promotion agreement with Kowa Pharmaceutical America, Inc. and collaboration agreement with Eddingpharm in greater China.

“On behalf of Amarin and its Board of Directors, it is with great pleasure that I announce Joe’s promotion and recognize his important contributions to the strength and development of Amarin,” stated John F. Thero, President and Chief Executive Officer of Amarin. “Joe’s skillful dedication and leadership have contributed meaningfully to our success and his efforts have made Amarin a leader on issues important to the life science industry and in support of our mission to improve the lives of patients.”

Mr. Kennedy joined Amarin with an impressive record of achievement in the life science industry. In 2010, he was recognized by the President of Ireland as one of the inaugural, “Irish Life Science 50,” which honored Irish-Americans for outstanding contributions to the industry. He served as Vice President, General Counsel at Transcept Pharmaceuticals, Inc., where he played a lead role negotiating the company’s strategic collaboration with Purdue Pharma, secured key patents, and helped design the strategy to obtain FDA approval for the company’s lead product following two Complete Response Letters from FDA. Mr. Kennedy also served as the chief legal officer of Eyetech Pharmaceuticals, Inc. through sale of the company to OSI Pharmaceuticals Inc. Previously, Mr. Kennedy served as Vice President and U.S. Counsel, Corporate Business Development, with Élan Corporation, plc where he helped acquire technologies, manage multiple collaborations and participated in the company’s sale of $2.0 billion in assets. Mr. Kennedy previously practiced law with Orrick, Herrington & Sutcliffe LLP where he represented investment banks and developing companies in initial public offerings and mergers and acquisitions.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin’s clinical program includes commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visitwww.amarincorp.com.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin contact information:
Michael Farrell
Investor Relations and Corporate Communications
Amarin Corporation
In U.S.: +1 (908) 719-1315
[email protected]

Graham Morrell
Trout Group
In U.S.: +1 (646) 378-2954
[email protected]

Media Inquiries
Lee Davies
In U.S.: +1 (212) 508-9651
[email protected]


Please enter your comment!
Please enter your name here